Polyrizon Ltd. closed a registered direct offering and concurrent private placement on September 4, 2026, raising approximately $4.0 million in aggregate gross proceeds from a single institutional investor. The company issued 333,333 units at a combined price of $12.00 per unit, consisting of ordinary shares and pre-funded warrants alongside common warrants with an exercise price of $12.00. Net proceeds will be used for general corporate purposes and working capital. Polyrizon Ltd. is a development-stage biotech company specializing in innovative intranasal hydrogels delivered via nasal sprays.
